Orlando, FL (PRWEB) January 05, 2013
The prescription drug resource center DrugRisk.com has added new information to its already comprehensive database for the blood thinner Pradaxa, after an Australian health advisory questioned whether the drug was safe enough for the government to supply it to citizens.
“DrugRisk’s goal is to improve patient safety through education with the latest drug warnings, recalls, studies and litigation news. Although most people never hear about drug warnings from other countries, these can be just as important as those in the U.S.,” explained DrugRisk representative Ryan Mayer.
Last month, Australia’s Pharmaceutical Benefits Advisory Committee (PBAC) warned that they may withdraw recommendations that the government continue to furnish prescriptions of Pradaxa.*
The Committee noted concerns that, while Pradaxa may have health and financial benefits over other anticoagulants, it may be prescribed for patients and at dosages not tested in clinical trials.
In the United States, experts disagree about the safety of Pradaxa bleeding risks. Last month the FDA updated warnings to say the drug carries the same risks as warfarin.** However, the New York Times also reported doctors’ concerns that Pradaxa led all medications for adverse reports and currently has no antidote for internal bleeding.***
Most common among the adverse reports were 6497 gastrointestinal side effects, 4910 gastrointestinal hemorrhages (bleeding) and 2941 central nervous system or cranial hemorrhaging problems. There were also 842 deaths attributed to the drug.****
Since September, the number of patients filing a Pradaxa lawsuit over internal bleeding has risen 50%.***** The cases have now been moved to a special federal court in Illinois, formally known as MDL No. 2
Copyright©2012 Vocus, Inc.
All rights reserved